44 results about "Adverse drug reaction" patented technology

A system and method for the automatic diagnosis of obstructive sleep apnea in a centralized hospital critical care monitoring system for the monitoring of a plurality of patients in at least one of a critical care, step down, and cardiac ward by telemetry. The system includes a central processor having a display, and a plurality of telemetry units for mounting with patients, each of the telemetry units has a plurality of sensors for connection with each patient, the telemetry unit is capable of the transmission of multiple signals derived from the sensors to the central processor, in one preferred embodiment the method comprising steps of programming the system to analyze the signals and to automatically identify the presence and severity of obstructive sleep apnea and to provide an indication of the identification.

The invention belongs to the technical field of pharmaceutical chemistry, and more specifically discloses a benzimidazole derivative, and a preparation method and pharmaceutical applications thereof. The benzimidazole derivative comprises ligustrazine and a NO donor derivative. In vivo, ligustrazine or NO can be released from the benzimidazole derivative quickly, so that effective synergistic effect with Azilsartan is achieved, anti-hypertension curative effect is improved, adverse reaction is reduced, ideal protection effect on livers and kidneys of patients is achieved, and the blank of the prior art is filled.

Provided is an oxyntomodulin analogue. The analogue comprises GCGR and GLP-1R dual agonist activity, improved enzymolysis stability and biological activity, and no adverse reactions. The analogue can be used to prepare medication for treating hyperphagia, obesity and diabetes.

The invention provides a method of evaluating tendency of adverse reactions of a drug. The method comprises the following steps of: excluding interference information according to structural characteristics of the drug and quantitative characteristics of an adverse reaction tendency value and establishing an evaluated quantitative relation model between the structural characteristics and the adverse reaction tendency value; and applying the model to evaluate safety of the drug, wherein the accuracy of evaluating the adverse reaction tendency value of the drug can be effectively increased and the consumption of scientific research resources is lowered. The method is targeted, can remarkably reduce the blindness of a common method of evaluating the adverse reaction tendency value, provides evaluated drug safety risk warn for safe monitoring in a research process of the drug and after the drug is marketed, and provides pre-warning to adverse reactions of the drug, so as to improve the foreseeability and the medical safety level of drug monitoring, and provide reference to personal medication.

The invention discloses application of dihydromyricetin in preparing a medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor. In particular, the application is to prepare medicines for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, preventing and treating arrest of bone marrow and baldness, resisting mutation, preventing and treating the generation of secondary tumors, preventing and treating tumor transfer, and preventing and treating breast cancer, cervical carcinoma, intestinal cancer and the like. The invention creatively finds that the dihydromyricetin has the effects of removing free radicals, inhibiting reaction chains of the free radicals, resisting the mutation, inhibiting the expression of the tumor gene, causing the death of tumor cells, preventing and treating the tumor generation, preventing and treating the secondary tumors and the transfer of the secondary tumors and preventing and treating infection. Therefore, as the medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, the dihydromyricetin can inhibit and alleviate chemical damage, prevent and treat damage of a mutagen and further prevent gene mutation or the secondary tumors; and by combination with the radiotherapy and chemotherapy, the effects of preventing untoward reactions in radiotherapy and chemotherapy of tumor and preventing generation of tumors are achieved.

The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for trating undesired physiological adverse reactions due to the administration of a therapeautic modecule containing the L-RNA. Alternatively, an endogeneous target RNA may also be split by the L-ribozyme.

The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for trating undesired physiological adverse reactions due to the administration of a therapeautic modecule containing the L-RNA. Alternatively, an endogeneous target RNA may also be split by the L-ribozyme.